A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
Epistemonikos ID: 87af0f6db5553bf398e8f9d23ca340a3b164e962
First added on: May 17, 2024